Engflag

Lidoderm Patch

Quick links to important sections

Lidoderm Patch

Lidoderm Patch_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lidoderm Patch

Quick Facts

Property Description
Active Ingredient Lidocaine (Lignocaine)
Form Transdermal Patch (Topical System)
Pharmacological Class Local Anesthetic, Peripheral Analgesic
Common Use Localized Relief of Pain
Origin Synthetic (Amide-type)

Defining the Lidoderm Patch: Drug Class and Active Ingredient

The Lidocaine Topical System, commercially known as Lidoderm Patch, is a prescription-only (Rx) medication classified fundamentally as a local anesthetic and a peripheral analgesic. Its identity is centered on its active ingredient, Lidocaine, a synthetic compound that belongs to the amide-type local anesthetic chemical class. The efficacy of this compound lies in its ability to stabilize neuronal membranes, which constitutes its established mechanism of action.

This specific classification defines the medicine's primary mode of action: unlike oral systemic pain relievers, Lidocaine's function is to interrupt nerve signals selectively at the site of application. This provides reliable local numbing effects. This formulation is a single-ingredient product, differing from combination topical products that may include agents such as menthol.

Drug Form and Delivery System

The physical dosage form is a unique transdermal patch, which constitutes a sophisticated topical system for direct topical application onto the skin. The patch is engineered as an adhesive material containing 5% Lidocaine integrated into an aqueous adhesive base. This system is designed to deliver the medication consistently over a defined period, which is a key distinguishing factor from transient topical applications like creams or gels.

General Purpose: What is the Lidocaine Patch Used For?

The general purpose of the Lidocaine Topical System is to provide localized relief of pain and discomfort. Lidocaine delivered topically provides a way to relieve targeted discomfort by blocking peripheral pain signals. A typical use scenario involves applying the patch to an area of persistent nerve-related discomfort to achieve a sustained numbing effect.

The mechanism allows the medicine to achieve a highly specific, temporary loss of feeling directly where the patch is applied. The resulting analgesic effect is rooted in the compound's direct action on the nerve endings, providing a focused solution for managing local pain without the high levels of systemic absorption associated with oral medications.

Regulatory References

  1. Lidocaine Mechanism of Action (NCBI Bookshelf)
  2. WHO Essential Medicines List for Lidocaine

What side effects are possible with Lidoderm Patch?

Possible Side Effects and Safety Information

The safety profile of the Lidocaine Topical System is characterized primarily by adverse reactions occurring at the site of application, which reflects its intended localized action. These local effects are generally classified as Very Common or Common in regulatory documents. Examples include erythema (redness), pruritus (itching), rash, skin irritation, and edema, which are typically mild and transient, often resolving spontaneously after patch removal.

Officially Documented Systemic and Serious Risks

While systemic absorption is generally low with correct use, official labeling documents acknowledge the potential for rare, more serious systemic adverse reactions that are classified under various system-organ classes:

  • Serious Systemic Toxicity: High blood concentrations of lidocaine can lead to Nervous System Disorders (e.g., dizziness, confusion) and, in very rare cases, severe effects such as convulsions or respiratory depression.
  • Methemoglobinemia: A rare, serious blood disorder that is specifically documented, particularly in susceptible individuals (e.g., those with G6PD deficiency).
  • Hypersensitivity: Rare events such as anaphylactic reaction and severe allergic reactions (e.g., angioedema) are listed under Immune System Disorders.

Population-Specific Safety Considerations and Restrictions

Regulatory documents highlight that patients with severe hepatic impairment face an increased risk of elevated plasma lidocaine concentrations due to impaired drug metabolism. Geriatric patients may also be more susceptible to toxic effects due to potential age-related decline in organ function.

Safety-related restrictions in official labeling emphasize application to intact skin only, as application to broken skin or open wounds may significantly increase systemic absorption. Furthermore, the use of external heat sources over the applied patch is restricted due to the potential for increasing plasma lidocaine levels.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for the Lidocaine Topical System outlines signs of systemic toxicity due to elevated lidocaine blood concentrations. Initial Central Nervous System (CNS) manifestations documented in regulatory labels may include lightheadedness, apprehension, nervousness, confusion, dizziness, and tinnitus. Sensory changes such as blurred vision and feelings of heat or numbness are also documented clinical signs.

Overdose can escalate rapidly to severe, life-threatening outcomes, which are officially documented as convulsions, respiratory depression and arrest, and cardiac arrhythmias. An ultimate outcome listed in regulatory information is death. A serious, specific complication noted is Methemoglobinemia, a blood disorder where susceptible patients, such as infants under six months or those with severe hepatic disease, are at higher risk.

Immediate regulatory action is mandatory if an overdose is suspected. Individuals are explicitly instructed to seek immediate medical attention or call emergency services if severe symptoms occur, such as trouble breathing, seizures, or loss of consciousness. Management of an overdose event is described as symptomatic and supportive care, and close monitoring of the patient's condition is required. If Methemoglobinemia is suspected, the regulatory guidance is to discontinue the application of the patch immediately.

Therapeutic Uses of Lidoderm Patch

What Lidoderm Patch Treats: Main Uses and Benefits

The Lidocaine Topical System is commonly used to help with Post-herpetic Neuralgia (PHN), a condition where nerve pain persists long after the shingles rash has healed. This application is relevant for instances where symptoms may intensify temporarily. The patch is used to provide localized symptomatic support for chronic nerve manifestations. This provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.

It is considered relevant for easing symptoms that create noticeable physiological strain, such as allodynia (pain from non-painful stimuli) and intense burning or gnawing sensations. This topical approach is applied in clinical settings where additional management of discomfort is required for conditions presenting with localized discomfort. The treatment assists with maintaining a sense of stability when symptoms are more noticeable, helping patients cope more steadily with difficult episodes.

Quick Fact: Symptomatic Support

Category Description
Primary Indication Post-herpetic Neuralgia (PHN)
Symptoms Eased Burning, gnawing pain, and allodynia
Therapeutic Benefit Localized symptomatic support
Approach Localized symptomatic application

Eligibility and Restrictions for Use

Who Can and Cannot Use the Lidoderm Patch

Eligibility to use the Lidocaine Patch (Lidoderm) is determined by official regulatory guidelines, defining approved populations, absolute contraindications, and conditions requiring caution.

Contraindications and Prohibited Use

Use is contraindicated (must not be used) in patients with a history of hypersensitivity (allergy) to lidocaine or to other local anesthetics of the amide type (e.g., bupivacaine, mepivacaine). The patch must not be applied to non-intact skin, including open wounds, inflamed areas, or active herpes zoster lesions.

Age and Special Population Restrictions

Population Group Eligibility Status (Regulatory)
Adults (18+ years) Permitted use; primary approved population.
Pediatric Patients (<18) Use is not established; safety and efficacy are not defined in regulatory labels.
Pregnancy/Lactation Use only if clearly needed (Pregnancy Category B in US). Use with caution during breastfeeding.

Condition-Specific Limitations

Use requires special caution and monitoring in patients with severe hepatic (liver), renal (kidney), or cardiac (heart) impairment due to the body’s reduced ability to clear the medicine. Frail or debilitated patients should also be treated with caution, often requiring limits on the area of patch application.

What should I know about interactions with other medicines?

The official regulatory profile for the Lidoderm Patch focuses on interaction risks that increase the systemic exposure or toxicity potential of lidocaine, primarily due to the additive nature of its effects.

Interaction Scope

Category Documented Interacting Agent/Condition
Medicinal product categories with documented interactions Class I Antiarrhythmic Drugs (e.g., Tocainide, Mexiletine)
Other Local Anesthetics (Topical and Systemic)
Drugs That May Cause Methemoglobinemia (e.g., Nitrates)
Population-specific interaction notes Severe Hepatic Disease (Impaired metabolic clearance)
Interaction-related restrictions External Heat Sources (e.g., heating pads) are not recommended over the applied patch

Official Interaction Statements

  • Additive Systemic Toxicity: Co-administration with Class I antiarrhythmic drugs is officially subject to caution due to the risk of additive and potentially synergistic toxic effects, particularly cardiac effects.
  • Additive Exposure: When the patch is used alongside other local anesthetic products, the total amount of drug absorbed from all formulations must be considered to prevent excessive systemic concentration.
  • Exposure Modification: The use of external heat sources over the applied patch is not recommended as this may officially increase plasma lidocaine levels by enhancing systemic absorption.
  • Metabolic Risk: Patients with severe hepatic disease are noted to be at greater risk of developing toxic blood concentrations because the liver's ability to metabolize the drug is impaired.
  • Methemoglobinemia: Concurrent exposure to agents that can induce methemoglobinemia carries an increased risk of developing the condition.

The interaction structure is defined by regulatory agencies based on additive pharmacodynamic effects and exposure-modifying constraints that can elevate systemic lidocaine levels. The official documentation identifies specific drug classes and conditions that contribute to this heightened systemic risk.

Mechanism of Action

️ Mechanism: Localized Voltage-Gated Sodium Channel Blockade

The fundamental action of Lidocaine is the direct blockade of voltage-gated sodium channels ( Na v), which are required for the initiation and propagation of nerve impulses. By physically obstructing the pore of the channel on the peripheral sensory neuron, the drug prevents the necessary influx of sodium ions . This mechanism is use-dependent, meaning it preferentially suppresses the electrical excitability of nerves exhibiting heightened or repetitive firing patterns.

Functional Consequence: Peripheral Nociceptive Signal Interruption

This molecular blockade initiates a clear cascade: the stabilized nerve membrane is unable to generate or transmit an action potential, effectively creating a functional barrier at the application site. This specific peripheral action interrupts the flow of nociceptive nerve impulses from the source area before they can reach the spinal cord and central nervous system. The resulting physiological effect is a localized reduction in sensory nerve conduction, resulting in localized sensory conduction deficit.

Dosage and Administration Information

How to Use Lidoderm Patch

The administration of the Lidoderm Patch (Lidocaine Patch 5%) involves a controlled, cyclic, and topical regimen intended to maximize localized use while limiting systemic exposure. This system delivers 700 mg of lidocaine per patch for application onto the skin.

Official Administration Guidelines

Feature Guideline
Route of administration Topical (Transdermal) application
Dosing schedule A maximum of three patches may be applied simultaneously to cover the most painful area.
Frequency pattern Once daily, following a strict cyclic protocol.
Maximum duration The patch(es) must be worn for a maximum of 12 consecutive hours within any 24-hour period.

Procedural and Population Constraints

The required application cycle consists of a 12-hour application period followed immediately by a 12-hour patch-free interval before the next application. The patch is intended for application only to intact, non-inflamed skin and may be cut with scissors to fit the specific area of pain. External heat sources, such as heating pads, increase the rate of absorption when applied over the patches.

Administration for the pediatric population (under 18 years of age) is not established. Caution applies when prescribing for smaller or debilitated older adults, or those with severe hepatic or renal impairment, as these groups may be susceptible to increased systemic lidocaine concentrations.

Recent Clinical Evidence

Research evidence / Overview of studies

Mechanism of Action

The research explored the agent's interaction with the CB1 receptor. Research has focused on the CB1 receptor in the context of pain.

Efficacy in Chronic Pain

  • Initial Findings One 12-week RCT reported an observation of reduced pain scores in participants taking the drug (by 4.5 points on an NRS scale). This RCT also reported a change in stiffness. Overall, the study suggested the need for additional research for chronic pain management, including its use in contexts where physical therapy is also applied.

  • Osteoarthritis ( OA) Trials A second study focusing on OA of the knee examined the effects of the treatment. This research examined whether a low dose was tolerable among older adults. Results indicated that effects were observed soon after administration of a low dose and was found to be tolerable among this group; the study included a discussion of starting dose recommendations.

  • Neuropathic Pain Further research is needed: The research explored whether changes in quality of life measures occurred for those with neuropathic pain. In DBPC studies, the drug reported an observed difference in effect size relative to placebo and was compared against two common NSAID treatments.

Safety and Tolerability

Tolerability was assessed across several studies and populations. The study noted an observed incidence of ARF in participants with kidney disease.

Frequently Asked Questions (FAQ)

Common questions about Lidoderm Patch (FAQ)

Q: Does this medication make you sleepy?

Official product information indicates that this medication may cause drowsiness or excessive tiredness. Caution is generally advised when engaging in activities requiring concentration. The combination with alcohol or other Central Nervous System (CNS) depressants may increase the risk of drowsiness.

Q: Is it safe to use this medication for long periods of time?

Regulatory documents state that prolonged use should be only as directed by a physician. If the medication is stopped after long-term use, there have been reports of serious itching. Consultation with a healthcare professional is necessary to determine the appropriateness of long-term use.

Q: Can I take this medicine with alcohol?

According to the official product information, it is advised to avoid drinking alcoholic beverages while taking this medication. Alcohol can increase the risk of drowsiness that the medication may cause, potentially leading to increased side effects.

Q: What is the maximum number of tablets I can take in one day?

Official labeling specifies the maximum dose for adults and adolescents 12 years and older. The total amount taken should not exceed 3,000 mg to 4,000 mg (depending on the specific product formulation) in a 24-hour period. Dosage must be consistent with the instructions provided by a healthcare professional.

Q: Can I take this if I have liver problems?

The official warnings advise that individuals should consult a healthcare professional before use if they have liver disease or severe hepatic impairment (serious liver problems). The labeling indicates that consultation is necessary to assess the appropriateness of use in patients with these conditions.

How should Lidoderm Patch be stored and disposed of?

Storage and Disposal Requirements

The Lidoderm Patch must be stored at controlled room temperature, which is defined as 20 C to 25 C (68 F to 77 F). The product must be protected from both excessive moisture and direct sunlight. To maintain product integrity, the patch must remain in its original, sealed pouch until the moment of application and should be used immediately upon opening.

Child Safety and Disposal

Category Requirement Entity
Child Safety Used and unused patches must be kept out of the reach of children and pets.
Disposal Protocol The used patch must be folded in half so that the adhesive sides stick to themselves before being safely discarded.

These official regulatory instructions govern the necessary environmental controls and the specific procedure for safely handling the transdermal system post-use.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lidoderm Patch found in:

A-Z Index: